| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/24/2001 | US6265390 Methods for expressing nucleic acid sequences using nucleic acid constructs comprising hypoxia response elements |
| 07/24/2001 | US6265375 Conformationally constrained backbone cyclized peptide analogs |
| 07/24/2001 | US6265215 Isolated peptides which complex with HLA-Cw16 and uses thereof |
| 07/24/2001 | US6265189 Expressing polypeptide in cell culture; insert gene into viral expression vector, transform cells, recover preferential polypeptide |
| 07/24/2001 | US6264978 Transdermal application system containing acetylsalicylic acid for antithrombotic therapy and cancer prophylaxis |
| 07/24/2001 | US6264958 Polynucleotide |
| 07/24/2001 | US6264948 Methods and compositions for inhibiting tumor cell growth |
| 07/24/2001 | US6264947 Genetic engineering; therapy for cancer, autoimmune diseases, reproduction, antiinflammatory agents |
| 07/24/2001 | US6264920 Tunable indocyanine dyes for biomedical applications |
| 07/24/2001 | US6264919 Restoring fluorescence; adding biocompatible solvent |
| 07/24/2001 | US6264917 Targeted ultrasound contrast agents |
| 07/24/2001 | CA2221753C Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast |
| 07/24/2001 | CA2218503C Arylsulfonyl hydroxamic acid derivatives |
| 07/24/2001 | CA2193454C Bioadhesive pharmaceutical composition for the controlled release of active ingredients |
| 07/24/2001 | CA2030162C Benzothiazepines |
| 07/19/2001 | WO2001051664A2 Method of detecting and characterizing a neoplasm |
| 07/19/2001 | WO2001051642A2 Dna modification proteins |
| 07/19/2001 | WO2001051641A1 Irak-4: compositions and methods of use |
| 07/19/2001 | WO2001051638A2 Drug metabolizing enzymes |
| 07/19/2001 | WO2001051636A2 Secreted proteins |
| 07/19/2001 | WO2001051635A2 Novel stra6 polypeptides |
| 07/19/2001 | WO2001051633A2 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 07/19/2001 | WO2001051619A2 Genetically modified fibroblast cell |
| 07/19/2001 | WO2001051608A2 Hybrid cells obtainable from antigen presenting cells |
| 07/19/2001 | WO2001051523A2 Anti-angiogenic proteins and fragments and methods of use thereof |
| 07/19/2001 | WO2001051515A2 Genes differentially expressed in breast cancer |
| 07/19/2001 | WO2001051512A2 Human and parasite orphan receptor proteins |
| 07/19/2001 | WO2001051503A1 Polynucleotides for inhibiting metastasis and tumor cell growth |
| 07/19/2001 | WO2001051488A1 Pyrimidine derivatives having antitumor effect |
| 07/19/2001 | WO2001051482A1 Extraction of flavonoids |
| 07/19/2001 | WO2001051473A1 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation |
| 07/19/2001 | WO2001051464A1 Novel vitamin d analogues |
| 07/19/2001 | WO2001051462A1 INHIBITORS OF THE ICE/Ced-3 FAMILY OF CYSTEINE PROTEASES |
| 07/19/2001 | WO2001051128A1 Inhibitors of prenyl-protein transferase |
| 07/19/2001 | WO2001051127A1 Inhibitors of prenyl-protein transferase |
| 07/19/2001 | WO2001051126A1 Inhibitors of prenyl-protein transferase |
| 07/19/2001 | WO2001051125A1 Inhibitors of prenyl-protein transferase |
| 07/19/2001 | WO2001051087A2 Novel treatment for eye disease |
| 07/19/2001 | WO2001051082A1 Composition of antigen and glycolipid adjuvant sublingual administration |
| 07/19/2001 | WO2001051081A1 In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent |
| 07/19/2001 | WO2001051079A1 Antigen-specific ige antibody production inhibitors |
| 07/19/2001 | WO2001051070A1 Physiologically active substance eem-s originating in mushrooms, process for producing the same and drugs |
| 07/19/2001 | WO2001051051A2 AGENTS, SUCH AS NICOTINAMIDE OR cADPR FOR THE TREATMENT OF SKIN DISORDERS |
| 07/19/2001 | WO2001051049A1 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders |
| 07/19/2001 | WO2001051048A1 Use of epigallocatechin-gallate for inhibiting angiogenesis |
| 07/19/2001 | WO2001051043A2 Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols |
| 07/19/2001 | WO2001051014A1 Pharmaceutical and cosmetic carrier or composition for topical application |
| 07/19/2001 | WO2001051003A2 Use of lipid conjugates in the treatment of disease |
| 07/19/2001 | WO2001050873A1 Thickened oil compositions of edible oil |
| 07/19/2001 | WO2001050848A2 Clonal propagation of primate offspring by embryo splitting |
| 07/19/2001 | WO2001044172A8 Salicylamides as serine protease and factor xa inhibitors |
| 07/19/2001 | WO2001014414A3 Human abc2 transporter and uses thereof |
| 07/19/2001 | WO2001012632A3 Phenanthroline-7-one derivatives and their therapeutic uses |
| 07/19/2001 | WO2001012631A3 Ascididemin derivatives and their therapeutic applications |
| 07/19/2001 | WO2001005969A3 Electron transfer proteins |
| 07/19/2001 | WO2001005353A3 USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS |
| 07/19/2001 | WO2001004297A3 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 07/19/2001 | WO2000073324A3 Modulation of gene expression in gastrointestinal inflammation |
| 07/19/2001 | WO2000071703A3 Inhibition of histone deacetylase |
| 07/19/2001 | WO2000071104A3 Use of bisphosphonic acids for treating angiogenesis |
| 07/19/2001 | WO2000055321B1 Vertebrate protein slit, dna sequence encoding it and uses thereof |
| 07/19/2001 | WO2000044782A3 Ewing's tumour antigen, nucleic acid and antibodies |
| 07/19/2001 | WO2000040229A3 Synergistic tumorcidal response induced by histamine |
| 07/19/2001 | WO2000031136A9 Antagonistic analogs of gh-rh inhibiting igf-i and -ii |
| 07/19/2001 | WO2000025808A9 Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists |
| 07/19/2001 | WO2000023573A9 Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
| 07/19/2001 | WO2000009616A8 Biologically active fraction of vegetable melanin, process for its production and its use |
| 07/19/2001 | WO1998033916A8 Secreted proteins and polynucleotides encoding them |
| 07/19/2001 | US20010008939 Also useful in treating viral infections; antiprotozoa (plasmodium) activity |
| 07/19/2001 | US20010008901 Nitrile derivatives that inhibit cathepsin K |
| 07/19/2001 | US20010008772 Lipid, nucleic acid complex |
| 07/19/2001 | US20010008625 Receptor binding conjugates |
| 07/19/2001 | DE10101543A1 Enhancing the antitumor activity of an amygdalin-containing material, especially loquat kernels, comprises roasting the material with far infrared radiation and fermenting it with microorganisms |
| 07/19/2001 | DE10001879A1 New benzoylguanidine derivatives are Na+/H+ exchange inhibitors useful for the treatment and prevention of e.g. ischemic disorders, infarction, arrhythmia, angina pectoris and stroke |
| 07/19/2001 | CA2823768A1 Hybrid cells |
| 07/19/2001 | CA2406722A1 Dna modification proteins |
| 07/19/2001 | CA2397741A1 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 07/19/2001 | CA2397481A1 Irak-4: compositions and methods of use |
| 07/19/2001 | CA2397340A1 Drug metabolizing enzymes |
| 07/19/2001 | CA2397334A1 Secreted proteins |
| 07/19/2001 | CA2397207A1 Novel stra6 polypeptides |
| 07/19/2001 | CA2397081A1 Novel vitamin d analogues |
| 07/19/2001 | CA2397068A1 Pharmaceutical and cosmetic carrier or composition for topical application |
| 07/19/2001 | CA2397053A1 Human and parasite orphan receptor proteins |
| 07/19/2001 | CA2396996A1 Genetically modified fibroblast cell |
| 07/19/2001 | CA2396384A1 In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent |
| 07/19/2001 | CA2396324A1 Pyrimidine derivatives having antitumor activity |
| 07/19/2001 | CA2396247A1 Clonal propagation of primate offspring by embryo splitting |
| 07/19/2001 | CA2396235A1 Anti-angiogenic proteins and fragments and methods of use thereof |
| 07/19/2001 | CA2396071A1 Thickened oil compositions of edible oil |
| 07/19/2001 | CA2395975A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 07/19/2001 | CA2395567A1 Novel treatment for eye disease |
| 07/19/2001 | CA2366621A1 Use of epigallocatechin-gallate for inhibiting angiogenesis |
| 07/18/2001 | EP1115879A1 Retroviral particles protected against complement mediated destruction |
| 07/18/2001 | EP1115878A1 Recombinant celo virus and celo virus dna |
| 07/18/2001 | EP1115877A1 Polynucleotide constructs and uses thereof |
| 07/18/2001 | EP1115876A2 Receptor based antagonists and methods of making and using |
| 07/18/2001 | EP1115866A1 Cystine knot growth factor mutants |
| 07/18/2001 | EP1115864A2 Human chaperone proteins |
| 07/18/2001 | EP1115860A2 Membrane-associated organizational proteins |